innohep®

LEO Pharma · FDA-approved active Small molecule

innohep® is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by LEO Pharma. It is currently FDA-approved for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of thromboembolism in patients with acute myocardial infarction. Also known as: Tinzaparin sodium, Tinzaparin.

Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.

Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of thromboembolism in patients with acute myocardial infarction.

At a glance

Generic name	innohep®
Also known as	Tinzaparin sodium, Tinzaparin
Sponsor	LEO Pharma
Drug class	Low-molecular-weight heparin (LMWH)
Target	Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Innohep (tinzaparin sodium) is a low-molecular-weight heparin (LMWH) derived from porcine intestinal mucosa. It potentiates the inhibition of coagulation factors, particularly factor Xa and thrombin, through its interaction with antithrombin III. This prevents thrombus formation and is used for thromboprophylaxis and treatment of venous thromboembolism.

Approved indications

• Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery
• Treatment of acute deep vein thrombosis and pulmonary embolism
• Prophylaxis of thromboembolism in patients with acute myocardial infarction

Common side effects

• Bleeding
• Thrombocytopenia
• Injection site hematoma
• Elevated liver enzymes

Key clinical trials

• Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis (PHASE4)
• Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (PHASE2)
• Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer (PHASE3)
• Therapeutic Anticoagulation Strategy for Acute Chest Syndrome (PHASE3)
• The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer (PHASE3)
• A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study (PHASE2)
• Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort (PHASE2)
• Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• innohep® CI brief — competitive landscape report
• innohep® updates RSS · CI watch RSS
• LEO Pharma portfolio CI

Frequently asked questions about innohep®

What is innohep®?

innohep® is a Low-molecular-weight heparin (LMWH) drug developed by LEO Pharma, indicated for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of thromboembolism in patients with acute myocardial infarction.

How does innohep® work?

Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.

What is innohep® used for?

innohep® is indicated for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of thromboembolism in patients with acute myocardial infarction.

Who makes innohep®?

innohep® is developed and marketed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).

Is innohep® also known as anything else?

innohep® is also known as Tinzaparin sodium, Tinzaparin.

What drug class is innohep® in?

innohep® belongs to the Low-molecular-weight heparin (LMWH) class. See all Low-molecular-weight heparin (LMWH) drugs at /class/low-molecular-weight-heparin-lmwh.

What development phase is innohep® in?

innohep® is FDA-approved (marketed).

What are the side effects of innohep®?

Common side effects of innohep® include Bleeding, Thrombocytopenia, Injection site hematoma, Elevated liver enzymes.

What does innohep® target?

innohep® targets Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets) and is a Low-molecular-weight heparin (LMWH).

Related

• Drug class: All Low-molecular-weight heparin (LMWH) drugs
• Target: All drugs targeting Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets)
• Manufacturer: LEO Pharma — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery
• Indication: Drugs for Treatment of acute deep vein thrombosis and pulmonary embolism
• Indication: Drugs for Prophylaxis of thromboembolism in patients with acute myocardial infarction
• Also known as: Tinzaparin sodium, Tinzaparin